Kymab has defeated an opposition by Regeneron against the grant of an Australian patent covering transgenic mouse platforms for antibody discovery on all grounds

Cambridge, UK; 2 September 2019: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that it has received a decision from the Australian Patent Office (IP Australia) rejecting on all grounds an opposition by Regeneron Pharmaceuticals Inc (“Regeneron”) against the grant of a Kymab patent covering genetically modified mice containing human-mouse chimeric antibody loci, humanized antibodies from such mice, cell lines for manufacturing antibodies and pharmaceuticals containing antibodies.